Australia Stock Exchange release from PHARMAUST : Update on Manufacture of MPL & Tablets for Clinical Trials
01/02/2022 22:25
Australia Stock Exchange release from PHARMAUST PAA.AX : Update on Manufacture of MPL & Tablets for Clinical Trials
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon jumps on potential for neurodegenerative drug approval
Brief: Neurizon Therapeutics' Ongoing Healey ALS Platform Trial Affirmed By FDA
Brief: Neurizon Therapeutics Says Dr Chris Bremer Commences As CEO
Brief: Neurizon Therapeutics Appoints Chris Bremer As Chief Executive Officer
Brief: Neurizon Therapeutics Enters Strategic Research And Development Financing Facility